Overview
Background
Over 6 years of experience in translational biomedical research, specialising in monoclonal antibody-based therapies, immuno-oncology, target discovery and theranostics in cancer. My main research focus is on targeted cancer therapies, understanding how target receptor endocytosis affects antibody drug conjugate (ADC) and radioligand therapy delivery, immune-mediated ADCC, and how combination therapies with immune checkpoint inhibitors can potentially improve therapeutic outcomes for patients.
Availability
- Dr Benedict Lum is:
- Available for supervision
Fields of research
Qualifications
- Bachelor (Honours) of Biomedical Sciences, The University of Queensland
- Doctor of Philosophy of Biomedical Science, The University of Queensland
Works
Search Professor Benedict Lum’s works on UQ eSpace
2026
Journal Article
Utilizing biorecognition to prime tumors for enhanced nanomedicine delivery of alpha therapies
Fletcher, Nicholas L., Chu, Weijing, Huda, Pie, Prior, Amber, S., Gayathri, Humphries, James, Howard, Christopher, Wood, James L., Zhang, Xiaoyan, Silva, Marina Silveira E., Lum, Benedict, Lim, Malcolm, Simpson, Fiona and Thurecht, Kristofer J. (2026). Utilizing biorecognition to prime tumors for enhanced nanomedicine delivery of alpha therapies. Journal of Controlled Release, 392 114708, 114708. doi: 10.1016/j.jconrel.2026.114708
2026
Journal Article
Pretargeted polymeric systems for conducting chemo-radiotherapy on glioblastoma: an evaluation of the impact of nanomedicine structure on bioorthogonal chemistry in vivo
Chu, Weijing, Ediriweera, Gayathri R., Prior, Amber, Huda, Pie, Lum, Benedict, Howard, Christopher B., Fletcher, Nicholas L., Bernhardt, Paul V. and Thurecht, Kristofer J. (2026). Pretargeted polymeric systems for conducting chemo-radiotherapy on glioblastoma: an evaluation of the impact of nanomedicine structure on bioorthogonal chemistry in vivo. Biomacromolecules, 27 (1), 205-216. doi: 10.1021/acs.biomac.5c01157
2024
Journal Article
Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors
Muraro, Elena, Montico, Barbara, Lum, Benedict, Colizzi, Francesca, Giurato, Giorgio, Salvati, Annamaria, Guerrieri, Roberto, Rizzo, Aurora, Comaro, Elisa, Canzonieri, Vincenzo, Anichini, Andrea, Del Vecchio, Michele, Mortarini, Roberta, Milione, Massimo, Weisz, Alessandro, Pizzichetta, Maria Antonietta, Simpson, Fiona, Dolcetti, Riccardo, Fratta, Elisabetta and Sigalotti, Luca (2024). Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors. Frontiers in Immunology, 15 1336566, 1-17. doi: 10.3389/fimmu.2024.1336566
2023
Other Outputs
Improving monoclonal antibody therapies with temporary and reversible endocytosis inhibition
Lum, Benedict (2023). Improving monoclonal antibody therapies with temporary and reversible endocytosis inhibition. PhD Thesis, Frazer Institute, The University of Queensland. doi: 10.14264/12d5eba
2023
Journal Article
Endocytosis in cancer and cancer therapy
Banushi, Blerida, Joseph, Shannon R., Lum, Benedict, Lee, Jason J. and Simpson, Fiona (2023). Endocytosis in cancer and cancer therapy. Nature Reviews Cancer, 23 (7), 1-24. doi: 10.1038/s41568-023-00574-6
2021
Journal Article
Adenoid cystic carcinoma: a review of clinical features, treatment targets and advancement in improving the immune response to monoclonal antibody therapy
Nightingale, James, Lum, Benedict, Ladwa, Rahul, Simpson, Fiona and Panizza, Benedict (2021). Adenoid cystic carcinoma: a review of clinical features, treatment targets and advancement in improving the immune response to monoclonal antibody therapy. Biochimica et Biophysica Acta. Reviews on Cancer, 1875 (2) 188523, 1-9. doi: 10.1016/j.bbcan.2021.188523
2020
Journal Article
Antibody/ligand-target receptor internalization assay protocol using fresh human or murine tumor ex vivo samples
Joseph, Shannon R., Lum, Benedict, Banushi, Blerida, Barry, Rachael, Panizza, Benedict, Walpole, Euan and Simpson, Fiona (2020). Antibody/ligand-target receptor internalization assay protocol using fresh human or murine tumor ex vivo samples. STAR Protocols, 1 (2) 100087, 100087. doi: 10.1016/j.xpro.2020.100087
2020
Journal Article
Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies
Chew, Hui Yi, De Lima, Priscila O., Gonzalez Cruz, Jazmina L., Banushi, Blerida, Echejoh, Godwins, Hu, Lingbo, Joseph, Shannon R., Lum, Benedict, Rae, James, O'Donnell, Jake S., Merida de Long, Lilia, Okano, Satomi, King, Brigid, Barry, Rachael, Moi, Davide, Mazzieri, Roberta, Thomas, Ranjeny, Souza-Fonseca-Guimaraes, Fernando, Foote, Matthew, McCluskey, Adam, Robinson, Phillip J., Frazer, Ian H., Saunders, Nicholas A., Parton, Robert G., Dolcetti, Riccardo, Cuff, Katharine, Martin, Jennifer H., Panizza, Benedict, Walpole, Euan ... Simpson, Fiona (2020). Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. Cell, 180 (5), 895-914.e27. doi: 10.1016/j.cell.2020.02.019
Supervision
Availability
- Dr Benedict Lum is:
- Available for supervision
Looking for a supervisor? Read our advice on how to choose a supervisor.
Available projects
-
Novel Technologies for Cell Nuclear Delivery of Radiopharmaceuticals
Double-strand DNA breaks are a critical process in the treatment of cancerous cells. Therapeutic radiopharmaceuticals facilitate this DNA damage through the emission of ionising radiation which is used to kill cancer cells in patients. Auger emitting radioisotopes produce radiation with high energy, capable of highly efficacious DNA damage, however these emissions typically only travel less than a cell diameter, thus requiring targeted cellular nuclear delivery. This project will allow you to work with leading Australian radiopharmaceutical company Telix Pharmaceuticals to develop a suite of radiopharmaceuticals aimed at targeted nuclear delivery. You will work across the preclinical pipeline, from synthesis and radiolabelling of these radiopharmaceuticals, to in vitro cell biology validation of their targeting and efficacy. This project offers an opportunity to collaborate directly with industry partners and address a roadblock in the translation of Auger-emitting radiopharmaceuticals. The candidate should have a strong background and interest in cellular biology, organic chemistry, biochemistry. This project can be tailored to lean further towards pre-clinical cellular in vitro validation or organic synthesis depending on your interests and expertise.
Media
Enquiries
For media enquiries about Dr Benedict Lum's areas of expertise, story ideas and help finding experts, contact our Media team: